Trial Profile

A Phase I Study to Evaluate the Safety and Tolerability of CRN04777 in Healthy Adult Volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 23 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CRN 04777 (Primary)
Indications Congenital hyperinsulinism
Focus Adverse reactions; First in man; Proof of concept
Sponsors Crinetics Pharmaceuticals

Most Recent Events

08 Jun 2022 According to a Crinetics Pharmaceuticals media release, data from this study will be presented as a narrated "Poster Plus" in ENDO 2022.
30 Mar 2022 According to a Crinetics Pharmaceuticals media release, the company will hold a conference call and live audio webcast today to discuss results from MAD cohorts.
30 Mar 2022 According to a Crinetics Pharmaceuticals media release, results from SAD portion were presented during the 2021 Congenital Hyperinsulinism International Virtual Research Conference.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com